“In addition, we gain a sophisticated pipeline of potential customers with expired contracts. Going forward, as we continue to prioritize commercial execution, we anticipate that there will be sufficient migration of the existing Ra Medical customers to our recurring business model, to positively impact our short and long-term growth.” “This transaction’s advantages include an opportunity to increase our current installed base by more than 40% as we welcome Ra Medical’s customers to our platform. Moccia, Chief Executive Officer of STRATA Skin Sciences. market for treating chronic skin diseases,” said Robert J. “As we sought opportunities to further drive our commercial growth through both organic and inorganic opportunities, Ra Medical's Pharos dermatology business stood out as an ideal fit, as the only other significant provider of excimer laser solutions available to the U.S. It also provides a highly synergistic path to gain additional placements for STRATA’s XTRAC excimer laser system. The transaction immediately provides STRATA with the opportunity to market its full business solution to Ra Medical’s existing customer base of 400 dermatology practices, thus making way for STRATA to substantially increase its recurring revenue base in the future. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, today announced the acquisition of the U.S. 16, 2021 (GLOBE NEWSWIRE) - STRATA Skin Sciences, Inc. Increases competitive positioning with more than 400 U.S. ![]() ![]() ![]() Delivers added long-term recurring revenue growth potential and prospective customer base.market for the treatment of chronic skin diseases Positions STRATA as the predominant provider of excimer laser treatments to address the $6 billion U.S.
0 Comments
Leave a Reply. |